Delirium Clinical Trials Review 2024: Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
27 sept. 2024 06h57 HE
|
Research and Markets
Dublin, Sept. 27, 2024 (GLOBE NEWSWIRE) -- The "Delirium - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering."Delirium - Global Clinical...
Cystic Fibrosis Clinical Trials Review 2024: Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
27 sept. 2024 06h55 HE
|
Research and Markets
Dublin, Sept. 27, 2024 (GLOBE NEWSWIRE) -- The "Cystic Fibrosis - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report...
Social Anxiety Disorder (SAD/Social Phobia) Clinical Trials Review 2024: Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
27 sept. 2024 06h29 HE
|
Research and Markets
Dublin, Sept. 27, 2024 (GLOBE NEWSWIRE) -- The "Social Anxiety Disorder (SAD/Social Phobia) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's...
Chronic Low Back Pain (CLBP) Global Clinical Trials Review 2024:Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
27 sept. 2024 05h47 HE
|
Research and Markets
Dublin, Sept. 27, 2024 (GLOBE NEWSWIRE) -- The "Chronic Low Back Pain (CLBP) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical...
ClinicalTrials.EU platform rolled out across Europe
25 sept. 2024 09h14 HE
|
ClinicalTrials.EU
The European Clinical Trials Information Network (ClinicalTrials.EU) has today announced its official rollout across the continent.
Anti-retroviral Drugs Market to hit USD 42.5 billion by 2032, says Global Market Insights Inc.
25 sept. 2024 06h00 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Anti-retroviral Drugs Market size will reach USD 42.5 billion by 2032. Growing awareness and early diagnosis of HIV will accelerate...
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
24 sept. 2024 07h30 HE
|
Wave Life Sciences USA, Inc.
Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two...
India Clinical Trials Market By Region, Competition, Forecast & Opportunities, 2020-2024 & 2024-2030
20 sept. 2024 04h59 HE
|
Research and Markets
Dublin, Sept. 20, 2024 (GLOBE NEWSWIRE) -- The "India Clinical Trials Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" report has been added to ResearchAndMarkets.com's...
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
19 sept. 2024 08h00 HE
|
AIM ImmunoTech Inc.
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no...
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
16 sept. 2024 09h00 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...